Effectiveness of high doses of simvastatin as monotherapy in mixed hyperlipidemia.
Twenty subjects with mixed hyperlipidemia participated in a 3-arm crossover trial to evaluate the effectiveness of high-dose simvastatin as monotherapy. Significant reductions were observed in atherogenic lipids and lipoproteins. The highest dose of simvastatin also resulted in significant increases in high-density lipoprotein cholesterol (21%) with a comparable increase in large, protective high-density lipoprotein particles.
Miller
M
M
Division of Cardiology, University of Maryland Medical Center, Baltimore, USA. mmiller@heart.umaryland.edu
Dolinar
C
C
Cromwell
W
W
Otvos
J D
JD
D004334:Drug Administration Schedule; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D008055:Lipids / Q000097:blood; D009682:Magnetic Resonance Spectroscopy; D019821:Simvastatin / Q000008:administration & dosage* / Q000627:therapeutic use
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D008055:Lipids; D019821:Simvastatin